vs
RLI CORP（RLI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是RLI CORP的1.7倍（$772.1M vs $465.7M），RLI CORP净利率更高（19.6% vs 12.7%，领先6.8%），RLI CORP同比增速更快（6.1% vs 5.9%），Revvity自由现金流更多（$161.8M vs $155.0M），过去两年Revvity的营收复合增速更高（9.0% vs 2.3%）
RLI Corp是一家总部位于美国伊利诺伊州皮奥里亚的专业保险公司，主营财产保险与意外伤害保险业务，深耕保险领域多年，凭借成熟的风险管控体系与定制化产品矩阵，为不同类型的客户提供全面可靠的风险保障服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RLI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$465.7M
营收增速更快
RLI
高出0.2%
5.9%
净利率更高
RLI
高出6.8%
12.7%
自由现金流更多
RVTY
多$6.8M
$155.0M
两年增速更快
RVTY
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $465.7M | $772.1M |
| 净利润 | $91.2M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 24.4% | 14.5% |
| 净利率 | 19.6% | 12.7% |
| 营收同比 | 6.1% | 5.9% |
| 净利润同比 | 123.1% | 3.9% |
| 每股收益（稀释后） | $1.00 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RLIRVTY
| Q4 25 | $465.7M | $772.1M | ||
| Q3 25 | $509.3M | $698.9M | ||
| Q2 25 | $499.8M | $720.3M | ||
| Q1 25 | $407.7M | $664.8M | ||
| Q4 24 | $439.1M | $729.4M | ||
| Q3 24 | $470.0M | $684.0M | ||
| Q2 24 | $416.4M | $691.7M | ||
| Q1 24 | $444.8M | $649.9M |
净利润RLIRVTY
| Q4 25 | $91.2M | $98.4M | ||
| Q3 25 | $124.6M | $46.7M | ||
| Q2 25 | $124.3M | $53.9M | ||
| Q1 25 | $63.2M | $42.2M | ||
| Q4 24 | $40.9M | $94.6M | ||
| Q3 24 | $95.0M | $94.4M | ||
| Q2 24 | $82.0M | $55.4M | ||
| Q1 24 | $127.9M | $26.0M |
毛利率RLIRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率RLIRVTY
| Q4 25 | 24.4% | 14.5% | ||
| Q3 25 | 30.9% | 11.7% | ||
| Q2 25 | 31.3% | 12.6% | ||
| Q1 25 | 19.3% | 10.9% | ||
| Q4 24 | 10.8% | 16.3% | ||
| Q3 24 | 24.9% | 14.3% | ||
| Q2 24 | 24.8% | 12.4% | ||
| Q1 24 | 36.0% | 6.8% |
净利率RLIRVTY
| Q4 25 | 19.6% | 12.7% | ||
| Q3 25 | 24.5% | 6.7% | ||
| Q2 25 | 24.9% | 7.5% | ||
| Q1 25 | 15.5% | 6.4% | ||
| Q4 24 | 9.3% | 13.0% | ||
| Q3 24 | 20.2% | 13.8% | ||
| Q2 24 | 19.7% | 8.0% | ||
| Q1 24 | 28.8% | 4.0% |
每股收益（稀释后）RLIRVTY
| Q4 25 | $1.00 | $0.86 | ||
| Q3 25 | $1.35 | $0.40 | ||
| Q2 25 | $1.34 | $0.46 | ||
| Q1 25 | $0.68 | $0.35 | ||
| Q4 24 | $-2.87 | $0.77 | ||
| Q3 24 | $2.06 | $0.77 | ||
| Q2 24 | $1.78 | $0.45 | ||
| Q1 24 | $2.77 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $7.3B |
| 总资产 | $6.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RLIRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务RLIRVTY
| Q4 25 | — | — | ||
| Q3 25 | $100.0M | — | ||
| Q2 25 | $100.0M | — | ||
| Q1 25 | $100.0M | — | ||
| Q4 24 | $100.0M | — | ||
| Q3 24 | $100.0M | — | ||
| Q2 24 | $100.0M | — | ||
| Q1 24 | $100.0M | — |
股东权益RLIRVTY
| Q4 25 | $1.8B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.6B | $7.6B | ||
| Q4 24 | $1.5B | $7.7B | ||
| Q3 24 | $1.7B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.5B | $7.8B |
总资产RLIRVTY
| Q4 25 | $6.2B | $12.2B | ||
| Q3 25 | $6.2B | $12.1B | ||
| Q2 25 | $6.0B | $12.4B | ||
| Q1 25 | $5.7B | $12.4B | ||
| Q4 24 | $5.6B | $12.4B | ||
| Q3 24 | $5.8B | $12.8B | ||
| Q2 24 | $5.5B | $13.4B | ||
| Q1 24 | $5.3B | $13.4B |
负债/权益比RLIRVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 0.07× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $156.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $155.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 33.3% | 21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.72× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $608.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RLIRVTY
| Q4 25 | $156.8M | $182.0M | ||
| Q3 25 | $179.2M | $138.5M | ||
| Q2 25 | $174.7M | $134.3M | ||
| Q1 25 | $103.5M | $128.2M | ||
| Q4 24 | $128.1M | $174.2M | ||
| Q3 24 | $219.4M | $147.9M | ||
| Q2 24 | $141.8M | $158.6M | ||
| Q1 24 | $70.9M | $147.6M |
自由现金流RLIRVTY
| Q4 25 | $155.0M | $161.8M | ||
| Q3 25 | $177.8M | $120.0M | ||
| Q2 25 | $173.4M | $115.5M | ||
| Q1 25 | $102.5M | $112.2M | ||
| Q4 24 | $127.6M | $149.8M | ||
| Q3 24 | $219.0M | $125.6M | ||
| Q2 24 | $139.1M | $136.6M | ||
| Q1 24 | $69.9M | $129.7M |
自由现金流率RLIRVTY
| Q4 25 | 33.3% | 21.0% | ||
| Q3 25 | 34.9% | 17.2% | ||
| Q2 25 | 34.7% | 16.0% | ||
| Q1 25 | 25.1% | 16.9% | ||
| Q4 24 | 29.0% | 20.5% | ||
| Q3 24 | 46.6% | 18.4% | ||
| Q2 24 | 33.4% | 19.7% | ||
| Q1 24 | 15.7% | 20.0% |
资本支出强度RLIRVTY
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.3% | 2.4% | ||
| Q4 24 | 0.1% | 3.4% | ||
| Q3 24 | 0.1% | 3.3% | ||
| Q2 24 | 0.7% | 3.2% | ||
| Q1 24 | 0.2% | 2.7% |
现金转化率RLIRVTY
| Q4 25 | 1.72× | 1.85× | ||
| Q3 25 | 1.44× | 2.97× | ||
| Q2 25 | 1.41× | 2.49× | ||
| Q1 25 | 1.64× | 3.03× | ||
| Q4 24 | 3.13× | 1.84× | ||
| Q3 24 | 2.31× | 1.57× | ||
| Q2 24 | 1.73× | 2.87× | ||
| Q1 24 | 0.55× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RLI
| Casualty Segment | $246.8M | 53% |
| Property Insurance Segment | $122.5M | 26% |
| Other | $59.3M | 13% |
| Surety Insurance Segment | $37.1M | 8% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
